Your browser doesn't support javascript.
loading
In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates.
Li, Dan; Yu, Hua; Huang, Xiangning; Long, Shanshan; Zhang, Jie.
Afiliación
  • Li D; School of Medicine, University of Electronic Science and Technology of China , Chengdu, China.
  • Yu H; Department of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu , Sichuan, China.
  • Huang X; Department of Laboratory Medicine, Medical Center Hospital of Qionglai City, Chengdu , Sichuan, China.
  • Long S; Department of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu , Sichuan, China.
  • Zhang J; Department of Laboratory Medicine, Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu , Sichuan, China.
Microbiol Spectr ; 11(6): e0280623, 2023 Dec 12.
Article en En | MEDLINE | ID: mdl-37982631
ABSTRACT
IMPORTANCE To our knowledge, this is the first study to report the in vitro activity of two novel antimicrobial drugs, including imipenem-relebactam (IMR) and aztreonam-avibactam (AZA), toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKP) strains. Our in vitro activity study revealed that only few antibacterial agents (including several novel agents) exhibit high antimicrobial activity toward carbapenem-resistant Klebsiella pneumoniae (CRKP) and CR-hvKP isolates. IMR and AZA may be promising therapeutic agents for the treatment of infections caused by CRKP and CR-hvKP isolates.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Klebsiella / Enterobacteriaceae Resistentes a los Carbapenémicos Límite: Humans Idioma: En Revista: Microbiol Spectr Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por Klebsiella / Enterobacteriaceae Resistentes a los Carbapenémicos Límite: Humans Idioma: En Revista: Microbiol Spectr Año: 2023 Tipo del documento: Article País de afiliación: China